Walsh William Robert, Oliver Rema A, Christou Chris, Lovric Vedran, Walsh Emma Rose, Prado Gustavo R, Haider Thomas
Surgical & Orthopaedic Research Laboratories, Prince of Wales Clinical School, UNSW Australia, Prince of Wales Hospital, Sydney, NSW, Australia.
Haider Biologics, San Diego, California, United States of America.
PLoS One. 2017 Jan 3;12(1):e0168883. doi: 10.1371/journal.pone.0168883. eCollection 2017.
The need for bone graft materials to fill bony voids or gaps that are not related to the intrinsic stability of the bone that arise due to trauma, tumors or osteolysis remains a clinically relevant and significant issue. The in vivo response of collagen-tricalcium phosphate bone graft substitutes was evaluated in a critical size cancellous defect model in skeletally mature rabbits. While the materials were chemically virtually identical, new bone formation, implant resorption and local in vivo responses were significantly different. Differences in the in vivo response may be due, in part, collagen source and processing which influences resorption profiles. Continued improvements in processing and manufacturing techniques of collagen-tricalcium phosphate bone graft substitutes can result in osteoconductive materials that support healing of critical size bone defects even in challenging pre-clinical models.
由于创伤、肿瘤或骨质溶解而出现的与骨的内在稳定性无关的骨缺损或间隙,需要骨移植材料来填充,这仍然是一个具有临床相关性和重要意义的问题。在骨骼成熟的兔子的临界尺寸松质骨缺损模型中评估了胶原-磷酸三钙骨移植替代物的体内反应。虽然这些材料在化学上几乎相同,但新骨形成、植入物吸收和局部体内反应却有显著差异。体内反应的差异可能部分归因于影响吸收曲线的胶原来源和加工过程。胶原-磷酸三钙骨移植替代物的加工和制造技术的持续改进可以产生骨传导材料,即使在具有挑战性的临床前模型中也能支持临界尺寸骨缺损的愈合。